Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Scientists discover genetic process that may allow ovarian cancer to resist chemotherapy

York University researchers have zeroed in on a genetic process that may allow ovarian cancer to resist chemotherapy.

3 Mar 2011

Research: Blocking two cell DNA repair routes at once can provide new way to treat bowel cancer

Cancer Research UK-funded scientists have discovered that blocking two cell DNA repair routes at once could provide a completely new way to treat bowel cancer and potentially other cancers, according to research published in Cancer Research, today.

2 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

SPIN program to help mothers produce sufficient breast milk for their premature infants

Approximately 50,000 premature babies weighing less than three pounds are born in the United States each year. These fragile newborns need the highest quality nutrition, which is why UC San Diego Health System developed the Supporting Premature Infant Nutrition program to help mothers produce sufficient breast milk for their premature infants.

24 Feb 2011

Cannabis Science extract treatments help kill cancer cells

Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells.

23 Feb 2011

Biologist investigates CAPV-EAE population for hereditary breast and ovary cancer

Between 5 % and 10 % of breast cancer cases are hereditary, arising because the patient inherits from the father or mother a mutation in a gene that is susceptible to causing the illness. BRCA1 and BRCA2 have already been identified as two of the genes to be monitored. It is estimated that 30 % of hereditary breast cancer cases are due to mutations in one of these two genes.

19 Feb 2011

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

Australian health care company Prima BioMed Ltd announced today that there has been an agreement for strategy and design of the Phase III clinical registration trial for the CVac™ immunotherapy therapeutic ovarian cancer vaccine.

19 Feb 2011

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

BD and UCLB enter agreement for development of new diagnostics for ovarian, breast cancer

UCL Business (UCLB), a wholly owned subsidiary of University College London (UCL), and BD (Becton, Dickinson and Company), a leading global medical technology company, announced today an agreement aimed at improving the early detection of ovarian and breast cancers to ultimately enable earlier and more effective treatment.

From BD (Becton, Dickinson and Company) 10 Feb 2011

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Heart disease is a silent killer, but new microchip technology from Rice University is expected to advance the art of diagnosis.

9 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Patients receiving cancer treatment may experience skin, hair, nail problems

A cancer diagnosis and subsequent treatment, which commonly includes chemotherapy or radiation, can be taxing physically and emotionally on any patient. If that is not enough, dermatologists are cautioning patients receiving cancer treatment and cancer survivors that they may experience a host of skin, hair or nail problems as a direct result of their therapy that may require additional treatment by a dermatologist.

5 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

New discovery: miR-429 regulatory RNA may be effective in fighting ovarian cancer

Cancer researchers have discovered that a type of regulatory RNA may be effective in fighting ovarian cancer. Ovarian cancer isn't typically discovered until it's in the advanced stages, where it is already spreading to other organs and is very difficult to fight with chemotherapy.

4 Feb 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product. EGEN-001 is under clinical development for the treatment of advanced recurrent ovarian cancer.

2 Feb 2011

Elsevier acquires Cancer Information Group's oncology journals portfolio

Elsevier, the leading global publisher of scientific, technical, and medical information products and services, announced today that it acquired the oncology portfolio of journals previously published by CIG Media Group LP., (operated as Cancer Information Group).

2 Feb 2011

New study to address causes and risk factors of ovarian cancer in African American women

University Hospitals Case Medical Center and Case Western Reserve University School of Medicine are conducting an important new study addressing the lack of knowledge about causes and risk factors for ovarian cancer in African American women. The five-year study is funded by the National Cancer Institute through Case Western Reserve University School of Medicine.

2 Feb 2011

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.

1 Feb 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Scientists discover genetic process that may allow ovarian cancer to resist chemotherapy

Research: Blocking two cell DNA repair routes at once can provide new way to treat bowel cancer

TCD announces first patient treated in its TCD-717 Phase I trial

SPIN program to help mothers produce sufficient breast milk for their premature infants

Cannabis Science extract treatments help kill cancer cells

Biologist investigates CAPV-EAE population for hereditary breast and ovary cancer

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

BD and UCLB enter agreement for development of new diagnostics for ovarian, breast cancer

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Patients receiving cancer treatment may experience skin, hair, nail problems

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Merck reports GAAP net income of $861 million for 2010

New discovery: miR-429 regulatory RNA may be effective in fighting ovarian cancer

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

Elsevier acquires Cancer Information Group's oncology journals portfolio

New study to address causes and risk factors of ovarian cancer in African American women

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in